SCYNEXIS, Inc. (SCYX)
USD 0.9
(-1.14%)
USD 0.9
(-1.14%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -19.35 Million USD | -795.29% |
| 2022 | 2.78 Million USD | 104.57% |
| 2021 | -60.85 Million USD | 16.86% |
| 2020 | -73.19 Million USD | -170.75% |
| 2019 | -27.03 Million USD | -842.14% |
| 2018 | 3.64 Million USD | 14.45% |
| 2017 | 3.18 Million USD | 114.87% |
| 2016 | -21.4 Million USD | 54.45% |
| 2015 | -46.98 Million USD | -45.72% |
| 2014 | -32.24 Million USD | -338.03% |
| 2013 | 13.54 Million USD | -43.7% |
| 2012 | 24.05 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -20.62 Million USD | -6.6% |
| 2024 Q2 | -10.83 Million USD | 47.5% |
| 2023 Q2 | -43.2 Million USD | -293.92% |
| 2023 Q1 | 22.28 Million USD | 700.57% |
| 2023 Q3 | -29.26 Million USD | 32.26% |
| 2023 FY | -19.35 Million USD | -795.29% |
| 2023 Q4 | -19.35 Million USD | 33.88% |
| 2022 Q1 | -47.46 Million USD | 22.01% |
| 2022 FY | 2.78 Million USD | 104.57% |
| 2022 Q4 | 2.78 Million USD | 113.81% |
| 2022 Q3 | -20.15 Million USD | 71.47% |
| 2022 Q2 | -70.66 Million USD | -48.88% |
| 2021 Q1 | -76.51 Million USD | -4.53% |
| 2021 Q3 | -57.39 Million USD | 16.51% |
| 2021 FY | -60.85 Million USD | 16.86% |
| 2021 Q4 | -60.85 Million USD | -6.04% |
| 2021 Q2 | -68.74 Million USD | 10.16% |
| 2020 Q4 | -73.19 Million USD | -470.09% |
| 2020 Q2 | -12.39 Million USD | -112.19% |
| 2020 Q3 | -12.84 Million USD | -3.6% |
| 2020 FY | -73.19 Million USD | -170.75% |
| 2020 Q1 | -5.84 Million USD | 78.4% |
| 2019 Q3 | 4.36 Million USD | 477.18% |
| 2019 FY | -27.03 Million USD | -842.14% |
| 2019 Q4 | -27.03 Million USD | -719.52% |
| 2019 Q2 | -1.15 Million USD | -113.35% |
| 2019 Q1 | 8.66 Million USD | 137.94% |
| 2018 Q4 | 3.64 Million USD | 427.02% |
| 2018 FY | 3.64 Million USD | 14.45% |
| 2018 Q1 | -12.46 Million USD | -491.45% |
| 2018 Q2 | 8.09 Million USD | 164.97% |
| 2018 Q3 | -1.11 Million USD | -113.76% |
| 2017 Q3 | 5.8 Million USD | -17.12% |
| 2017 Q4 | 3.18 Million USD | -45.15% |
| 2017 FY | 3.18 Million USD | 114.87% |
| 2017 Q1 | -5.55 Million USD | 74.04% |
| 2017 Q2 | 7 Million USD | 226.03% |
| 2016 FY | -21.4 Million USD | 54.45% |
| 2016 Q2 | -37.86 Million USD | 0.4% |
| 2016 Q1 | -38.01 Million USD | 19.09% |
| 2016 Q4 | -21.4 Million USD | -36.84% |
| 2016 Q3 | -15.64 Million USD | 58.69% |
| 2015 Q4 | -46.98 Million USD | 12.61% |
| 2015 Q2 | -57.05 Million USD | -106.58% |
| 2015 Q1 | -27.62 Million USD | 14.34% |
| 2015 FY | -46.98 Million USD | -45.72% |
| 2015 Q3 | -53.76 Million USD | 5.77% |
| 2014 Q1 | 14.35 Million USD | 5.94% |
| 2014 FY | -32.24 Million USD | -338.03% |
| 2014 Q4 | -32.24 Million USD | 5.27% |
| 2014 Q3 | -34.03 Million USD | 11.42% |
| 2014 Q2 | -38.42 Million USD | -367.76% |
| 2013 Q1 | 2.38 Million USD | 0.0% |
| 2013 Q4 | 13.54 Million USD | 0.0% |
| 2013 FY | 13.54 Million USD | -43.7% |
| 2012 FY | 24.05 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 435.33 Million USD | 104.445% |
| China SXT Pharmaceuticals, Inc. | -9.42 Million USD | -105.202% |
| Embecta Corp. | 1.31 Billion USD | 101.475% |
| Pacira BioSciences, Inc. | 432.74 Million USD | 104.471% |
| PainReform Ltd. | -7.95 Million USD | -143.396% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | -23.764% |
| Journey Medical Corporation | -9.7 Million USD | -99.3% |
| Safety Shot Inc | -2.28 Million USD | -747.059% |
| Alpha Teknova, Inc. | 1.97 Million USD | 1080.243% |
| Bright Green Corporation | 1.84 Million USD | 1150.646% |
| Procaps Group, S.A. | 242.93 Million USD | 107.965% |
| Alvotech | 1.06 Billion USD | 101.818% |
| ANI Pharmaceuticals, Inc. | 94.2 Million USD | 120.54% |
| Aquestive Therapeutics, Inc. | 74.95 Million USD | 125.817% |
| Cosmos Health Inc. | 8.59 Million USD | 325.242% |
| Dynavax Technologies Corporation | 106.63 Million USD | 118.146% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | 104.218% |
| Intra-Cellular Therapies, Inc. | -130.82 Million USD | 85.21% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | -23.764% |
| Theratechnologies Inc. | 24.87 Million USD | 177.801% |
| Harrow Health, Inc. | 116.41 Million USD | 116.621% |
| Sonoma Pharmaceuticals, Inc. | -2.52 Million USD | -667.857% |
| Biofrontera Inc. | 4.05 Million USD | 577.071% |
| DURECT Corporation | -7.65 Million USD | -152.809% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 42.285% |
| Cronos Group Inc. | -663.32 Million USD | 97.083% |
| OptiNose, Inc. | 58.06 Million USD | 133.325% |
| Ironwood Pharmaceuticals, Inc. | 623.38 Million USD | 103.104% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | -32.789% |
| RedHill Biopharma Ltd. | -5.18 Million USD | -273.118% |
| Organogenesis Holdings Inc. | 15.01 Million USD | 228.888% |
| Guardion Health Sciences, Inc. | -6.35 Million USD | -204.262% |
| Cumberland Pharmaceuticals Inc. | 106.85 Thousand USD | 18207.974% |
| Radius Health, Inc. | 359.28 Million USD | 105.386% |
| Universe Pharmaceuticals INC | 197.2 Thousand USD | 9911.925% |
| ProPhase Labs, Inc. | 19.23 Million USD | 200.619% |
| Phibro Animal Health Corporation | 454.84 Million USD | 104.254% |
| Procaps Group S.A. | 242.93 Million USD | 107.965% |
| TherapeuticsMD, Inc. | 3.67 Million USD | 626.101% |
| Viatris Inc. | 17.13 Billion USD | 100.113% |
| Rockwell Medical, Inc. | 4.45 Million USD | 534.246% |
| Aytu BioPharma, Inc. | -4.87 Million USD | -296.76% |
| SIGA Technologies, Inc. | -148.68 Million USD | 86.986% |
| Tilray Brands, Inc. | 158.97 Million USD | 112.172% |
| Lifecore Biomedical, Inc. | 121.89 Million USD | 115.874% |
| Shineco, Inc. | 29.29 Million USD | 166.063% |
| PetIQ, Inc. | 351.93 Million USD | 105.498% |
| Regencell Bioscience Holdings Limited | -2.9 Million USD | -566.913% |
| Incannex Healthcare Limited | -5.48 Million USD | -252.78% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | 110.914% |
| Alimera Sciences, Inc. | 55.3 Million USD | 134.985% |
| Silver Spike Investment Corp. | -32.61 Million USD | 40.665% |
| Assertio Holdings, Inc. | -32.52 Million USD | 40.515% |
| Shuttle Pharmaceuticals Holdings, Inc. | -1.48 Million USD | -1199.773% |
| Petros Pharmaceuticals, Inc. | -5.06 Million USD | -282.382% |
| Clever Leaves Holdings Inc. | -4.81 Million USD | -301.953% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | -135.588% |
| Avadel Pharmaceuticals plc | 4.21 Million USD | 558.857% |
| Hempacco Co., Inc. | 13.61 Million USD | 242.126% |
| Talphera, Inc. | -5.72 Million USD | -238.228% |
| Alvotech | 1.06 Billion USD | 101.818% |
| Eagle Pharmaceuticals, Inc. | 7.14 Million USD | 370.819% |
| Lantheus Holdings, Inc. | -96.71 Million USD | 79.992% |
| Currenc Group, Inc. | -16.57 Million USD | -16.755% |
| Kamada Ltd. | -46.43 Million USD | 58.326% |
| Indivior PLC | -33.95 Million USD | 43.008% |
| Evoke Pharma, Inc. | 260.57 Thousand USD | 7525.914% |
| Flora Growth Corp. | -713 Thousand USD | -2613.885% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | -135.588% |
| Evolus, Inc. | 63.7 Million USD | 130.373% |
| HUTCHMED (China) Limited | -197.45 Million USD | 90.2% |
| Amphastar Pharmaceuticals, Inc. | 479.11 Million USD | 104.039% |
| Akanda Corp. | 3.9 Million USD | 595.529% |